Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Arbutus Biopharma Has Dosed The First Patient In The Additional Treatment Arm Of The AB-729 Phase 2a Triple Combination Clinical Trial That Has Been Expanded To Include A Pd-1 Monoclonal Antibody, Opdivo (Nivolumab)

Author: Benzinga Newsdesk | June 21, 2023 07:33am

The objective of the additional treatment arm is to assess if a low dose of nivolumab, in combination with the booster dose(s) of Vaccitech's VTP-300, will further stimulate immune mediated reduction of HBsAg after the initial treatment with AB-729 and ongoing nucleos(t)ide analogue (NA) therapy in patients with chronic hepatitis B infection (cHBV).

Posted In: ABUS VACC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist